CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, an activated antibody-drug conjugates (ADC) directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, an activated ADC targeting CD71, also known as the transferrin receptor 1; and BMS-986249, which is a Probody version of ipilimumab that developed into a randomized Phase 2 study in combination with the PD-1 inhibitor nivolumab in patients with metastatic melanoma. The CTMX stock yearly return is shown above.
The yearly return on the CTMX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CTMX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|